__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Beovu is indicated in adults for the treatment of neovascular (wet) AMD.1,2

 

Over 230,000 brolucizumab injections estimated to have been administered worldwide since launch*2

*The numbers of Beovu units sold since October 2019 until May 2021.3

recommended by nice

reviewed by smc

 

AMD, age-related macular degeneration; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium.

References

  1. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Great Britain, December 2021.
  2. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Northern Ireland, November 2021.
  3. Novartis Data on File. BRODOF21-003, 2021.
  4. National institute for Health and Care Excellence (2021) Brolucizumab for treating wet age-related macular degeneration (NICE guideline 672). Available at https://www.nice.org.uk/guidance/ta672. [Accessed December 2021].
  5. Scottish Medicines Consortium. Available at https://www.scottishmedicines.org.uk/medicines-advice/brolucizumab-beovu-full-smc2272/ [Accessed December 2021]. 
Rate this content: 
No votes yet
UK | December 2021 | 140363-2
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]